Welcome to Native Cardio, Inc!
London – March 3, 2020 – Finalists for the 5th Annual Citeline Awards (previously known as the CARE Awards) have been revealed by Informa Pharma Intelligence. The announcement comes ahead of the planned dinner and awards ceremony on Thursday, April 30, 2020 in Boston,...
Postoperative atrial fibrillation (POAF) is the most frequent complication after cardiac surgery, occurring in up to 60% of patients. In addition, the incidence of POAF seems to be increasing, an aging population being the most significant reason. POAF is a serious concern and MUST BE TREATED because of the potential negative outcomes, which include: an increased risk for re-intubation, heart failure, stroke, ventricular arrhythmias and even death.
Current Treatment Options May Have Serious Side Effects
Despite recent improvements in medical and cardiac surgical techniques, POAF remains a major complication that is responsible for patient suffering, increased hospital stays and increased hospital costs. The current treatment regimens for POAF, a combination of intravenous (IV) antiarrhythmic drugs and external electrocardioversion, are in general successful in restoring a normal sinus rhythm to the heart. However, there are a number of serious side effects and drawbacks inherent to these treatments, which include: toxicity of the drugs administered and burns and pain related to external cardioversion.
Our Mission Statement
Native Cardio is a medical device/pharmaceutical development company committed to restoring quality of life to patients. As a company, we embrace the ever-changing healthcare environment by identifying current and future unmet needs. We then design and develop innovative medical products to address these unmet needs. Our goal is to utilize the latest technology to develop products that use a minimally invasive medical pathway to treat patients and that are cost efficient for both the patient and the healthcare delivery system.